Xu

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 IN RE FIBROGEN, INC., SECURITIES Case No. 21-cv-02623-EMC

LITIGATION.

ORDER DENYING DEFENDANTS’

MOTION TO DISMISS Docket Nos. 106-107, 109

12 13 I. INTRODUCTION Plaintiffs filed this lawsuit against FibroGen and its current Chief Executive Officer Enrique Conterno, former Interim Chief Executive Officer James Schoeneck, former Chief Medical Officer K. Peony Yu1, current Chief Medical Officer Mark Eisner, and former Chief Financial Officer Pat Cotroneo2 (collectively, “Individual Defendants”)3, for violations of Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder against the Individual Defendants, for 96 allegedly false and misleading statements between December 20, 2018 and July 15, 2021 (the “Class Period”). Plaintiffs filed this action on behalf of all investors who purchased or otherwise acquired

24 1 Dr. Yu was the Chief Medical Officer between…